Abstract

BackgroundCervical cancer is frequently detected gynecological cancer all over the world. This study was designed to develop a prognostic signature for an effective prediction of cervical cancer prognosis.MethodsDifferentially expressed genes (DEGs) were identified based on copy number variation (CNV) data and expression profiles from different databases. A prognostic model was constructed and further optimized by stepwise Akaike information criterion (stepAIC). The model was then evaluated in three groups (training group, test group and validation group). Functional analysis and immune analysis were used to assess the difference between high-risk and low-risk groups.ResultsThe study developed a 5-gene prognostic model that could accurately classify cervical cancer samples into high-risk and low-risk groups with distinctly different prognosis. Low-risk group exhibited more favorable prognosis and higher immune infiltration than high-risk group. Both univariate and multivariate Cox regression analysis showed that the risk score was an independent risk factor for cervical cancer.ConclusionsThe 5-gene prognostic signature could serve as a predictor for identifying high-risk cervical cancer patients, and provided potential direction for studying the mechanism or drug targets of cervical cancer. The integrated analysis of CNV and mRNA expanded a new perspective for exploring prognostic signatures in cervical cancer.

Highlights

  • IntroductionThis study was designed to develop a prognostic signature for an effective prediction of cervical cancer prognosis

  • Cervical cancer is frequently detected gynecological cancer all over the world

  • Identification of Differentially expressed genes (DEGs) based on copy number variation (CNV) data and expression profiles For CNV data in The Cancer Genome Atlas (TCGA) dataset, we analyzed the CNV of each sample by comparing with normal samples, and 6608 differential CNVs containing 6608 genes were screened (P < 0.05)

Read more

Summary

Introduction

This study was designed to develop a prognostic signature for an effective prediction of cervical cancer prognosis. Liu et al BMC Cancer (2022) 22:192 evaluate the prognosis of cervical cancer patients. Prognostic signature based on copy number variations (CNVs) has not been investigated before. A number of studies have demonstrated that CNVs are involved in tumorgenesis in many cancer types, such as lung cancer [10], leukaemia [11] and breast cancer [12]. Immunotherapy is a potentially effective strategy for cervical cancer patients with metastasis. Immune checkpoint blockade such as programmed death receptor-1 (PD-1) and CTLA-4 inhibitors has been seen as re-activators for T cell activation [15]. There are ongoing clinical trials exploring immune checkpoint inhibitors for aggressive cervical cancer

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call